BIO-TECHNE Corp 8K

Bio-Techne entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, valuing the company at about $11.3 billion, with closing targeted for late 2026 or early 2027 subject to customary approvals.

On June 25, 2026, Bio-Techne Corporation announced that it has entered into a definitive merger agreement under which Merck KGaA, Darmstadt, Germany will acquire Bio-Techne for $73 per share in cash, implying an enterprise value of approximately $11.3 billion (EUR 9.9 billion) and a 36% premium to Bio-Techne’s one‑month VWAP; the transaction, funded with cash on hand and new debt, has been approved by both companies’ boards and is expected to close by late 2026 or early 2027 subject to shareholder and regulatory approvals, with Merck projecting immediate accretion to sales growth and EBITDA pre margin, EPS pre accretion by year three, and about EUR 140 million of annual cost synergies fully realized by year three after closing, while combining complementary life science tools, multi‑omics, analytical and cell and gene therapy capabilities and expanding Bio-Techne’s global reach.

Filing Facts

CIK

842023

Ticker

TECH

Form

8K

Source Type

sec

Accession

0001999371-26-013429

Alert Tier

8